Effects of nateglinide and acarbose on glycemic excursions in standardized carbohydrate and mixed‑meal tests in drug‑naïve type 2 diabetic patients

Li,Hai; Xu,Wenming; Liu,Juan; Chen,Ailing; Liao,Zhihong; Li,Yanbing

doi:10.3892/br.2013.156

November-December 2013 Volume 1 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-December 2013 Volume 1 Issue 6

Full Size Image

Article

Effects of nateglinide and acarbose on glycemic excursions in standardized carbohydrate and mixed‑meal tests in drug‑naïve type 2 diabetic patients

Authors:
- Hai Li
- Wenming Xu
- Juan Liu
- Ailing Chen
- Zhihong Liao
- Yanbing Li
View Affiliations / Copyright

Affiliations: Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China
Pages: 913-917
|
Published online on: August 7, 2013

https://doi.org/10.3892/br.2013.156
Expand metrics +

Abstract

The aim of this study was to compare the effects of nateglinide and acarbose on glycemic excursions and postprandial glucose profiles with different types of meals (standardized carbohydrate and mixed meals) in drug‑naïve type 2 diabetic patients. A randomized, parallel‑group prospective design clinical trial was conducted and a total of 39 drug‑naïve patients (16 males and 23 females, aged 56.7±10.2 years) were enrolled. The patients were randomly divided into group A [nateglinide 120 mg three times daily (t.i.d.), n=19] and group B (acarbose 50 mg t.i.d., n=20). the standardized carbohydrate and mixed‑meal tests were performed at baseline and at the end of study. Continuous glucose monitoring system (CGMS) data were recorded. Various parameters that measure glucose variability were derived from the CGMS data. In the standardized carbohydrate meal tests, the postprandial glucose excursions (PPGEs) were significantly decreased in the two groups after 12 weeks of treatment (P<0.05), whereas the decrease was more prominent in the acarbose compared to the nateglinide group (P=0.138). In the mixed‑meal tests, the mean sensor glucose values [24‑h mean blood glucose (MBG)] were signiﬁcantly decreased in the two groups after 12 weeks of treatment (P<0.05) and the parameters of glucose excursions, including standardized deviation (SD), largest amplitude of glycemic excursion (LAGE), mean of daily differences (MODD) and mean amplitude of glycemic excursion (MAGE), were reduced in the two groups. However, the decreases in SD and LAGE in the nateglinide group were statistically significant, whereas in the acarbose group only the decreases in LAGE were statistically significant. The efficiency of nateglinide or acarbose in lowering postprandial 120‑min hyperglycemia were similar in the standardized carbohydrate meal test. However, acarbose was more efficient in lowering postprandial 30‑ and 60‑min hyperglycemia (P<0.05) compared to nateglinide. The fasting and postprandial total cholesterol (TC), triglyceride (TG) and low‑density lipoprotein cholesterol (LDL‑C) had a tendency to decrease from the baseline after 12 weeks of treatment with nateglinide, whereas fasting and postprandial high‑density lipoprotein cholesterol (HDL‑C) had a tendency to increase. Acarbose did not affect the fasting or postprandial lipid profiles after 12 weeks of treatment (P>0.05). in conclusion, nateglinide and acarbose effectively improved postprandial glycemic control, although acarbose was shown to be more efficient in controlling early (30 and 60 min) postprandial glucose excursions in the carbohydrate meal test, whereas nateglinide was shown to be superior to acarbose in controlling postprandial glucose excursions in the mixed‑meal test.

View Figures

View References

1	Brownlee M and Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 295:1707–1708. 2006. View Article : Google Scholar : PubMed/NCBI
2	Hirsch IB: Glycemic variability: it’s not just about A1C anymore! Diabetes Technol Ther. 7:780–783. 2005.
3	Ceriello A and Ihnat MA: ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med. 27:862–867. 2010.
4	Monnier L, Colette C and Owens DR: Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol. 2:1094–1100. 2008. View Article : Google Scholar : PubMed/NCBI
5	Gribble FM, Manley SE and Levy JC: Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care. 24:1221–1225. 2001. View Article : Google Scholar : PubMed/NCBI
6	Kim MK, Suk JH, Kwon MJ, et al: Nateglinide and acarbose for postprandial glycemic control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes Res Clin Pract. 92:322–328. 2011. View Article : Google Scholar : PubMed/NCBI
7	Hazama Y, Matsuhisa M, Ohtoshi K, et al: Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res Clin Pract. 71:251–255. 2006. View Article : Google Scholar : PubMed/NCBI
8	Chiasson JL, Josse RG, Hunt JA, et al: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 121:928–935. 1994. View Article : Google Scholar : PubMed/NCBI
9	Feinbock C, Luger A, Klingler A, et al: Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. Diabetes Nutr Metab. 16:214–221. 2003.PubMed/NCBI
10	Calles-Escandon J and Robbins DC: Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes. 36:1167–1172. 1987. View Article : Google Scholar : PubMed/NCBI
11	Pratley RE and Weyer C: The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 44:929–945. 2001. View Article : Google Scholar : PubMed/NCBI
12	Del Prato S: Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia. 46:M2–M8. 2003.PubMed/NCBI
13	Owens DR, Cozma LS and Luzio SD: Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. Diabet Nutr Met. 15(Suppl 6): 19–27. 2002.PubMed/NCBI
14	Bruttomesso D, Pianta A, Mari A, et al: Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes. 48:99–105. 1999. View Article : Google Scholar : PubMed/NCBI
15	Dimitriadis G, Boutati E, Lambadiari V, et al: Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism. Eur J Clin Invest. 34:490–497. 2004. View Article : Google Scholar : PubMed/NCBI
16	Pratley RE, Foley JE and Dunning BE: Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des. 7:1375–1397. 2001. View Article : Google Scholar : PubMed/NCBI
17	Hanefeld M, Bouter KP, Dickinson S and Guitard C: Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 23:202–207. 2000. View Article : Google Scholar : PubMed/NCBI
18	Saloranta C, Guitard C, Pecher E, et al: Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care. 25:2141–2146. 2002. View Article : Google Scholar : PubMed/NCBI
19	Hollander PA, Schwartz SL, Gatlin MR, et al: Importance of early insulin secretion comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care. 24:983–988. 2001. View Article : Google Scholar : PubMed/NCBI
20	Saloranta C, Hershon K, Ball M, et al: Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab. 87:4171–4176. 2002. View Article : Google Scholar : PubMed/NCBI
21	Gao HW, Xie C, Wang HN, et al: Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. Acta Pharmacol Sin. 28:534–539. 2007. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effects of nateglinide and acarbose on glycemic excursions in standardized carbohydrate and mixed‑meal tests in drug‑naïve type 2 diabetic patients

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles